{"title":"Efficacy of drug-coated balloon for repeated short-term restenosis of dialysis arteriovenous fistulas.","authors":"Takanori Maeda, Koji Kuroda, Makoto Takemoto, Wataru Fujimoto, Soichiro Yamashita, Junichi Imanishi, Masamichi Iwasaki, Takafumi Todoroki, Masanori Okuda","doi":"10.1177/20584601251352987","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Drug-coated balloons (DCB) are used for vascular access interventional therapy (VAIVT). However, few studies on patients with repeated short-term restenosis after VAIVT using a standard balloon (SB) have been reported, and the effect of DCB use on patency in these patients remains unclear.</p><p><strong>Purpose: </strong>This study aimed to evaluate the efficacy of DCB in patients with repeated short-term restenosis after VAIVT with SB.</p><p><strong>Materials and methods: </strong>This was a single-center retrospective study. We enrolled 50 consecutive patients who suffered two consecutive restenosis episodes within 6 months after VAIVT with SB. In the third session, patients were treated with DCB or SB. Target lesion revascularization (TLR) was evaluated for 1 year after the third session, with the primary endpoint being the TLR-free rate at 6 months after VAIVT.</p><p><strong>Results: </strong>At the third procedure, 24 patients were treated with DCB (DCB group), whereas 26 were treated with SB (SB group). The TLR-free rates at 6 months and 1-year were significantly higher in the DCB group than in the SB group (79.2% vs 26.9%, <i>p</i> < .001; and 41.7% vs 7.7%, <i>p</i> = .005). In the DCB group, a significant correlation was observed between the TLR duration from VAIVT with DCB and the prerestenosis duration before DCB treatment.</p><p><strong>Conclusions: </strong>Among patients with repeated short-term restenosis after VAIVT, DCB use significantly improved short-term patency compared with that after SB use. DCB may help extend the period between sessions, which are repeated in the short term, to an acceptable length.</p>","PeriodicalId":72063,"journal":{"name":"Acta radiologica open","volume":"14 6","pages":"20584601251352987"},"PeriodicalIF":1.0000,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179460/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta radiologica open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20584601251352987","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Drug-coated balloons (DCB) are used for vascular access interventional therapy (VAIVT). However, few studies on patients with repeated short-term restenosis after VAIVT using a standard balloon (SB) have been reported, and the effect of DCB use on patency in these patients remains unclear.
Purpose: This study aimed to evaluate the efficacy of DCB in patients with repeated short-term restenosis after VAIVT with SB.
Materials and methods: This was a single-center retrospective study. We enrolled 50 consecutive patients who suffered two consecutive restenosis episodes within 6 months after VAIVT with SB. In the third session, patients were treated with DCB or SB. Target lesion revascularization (TLR) was evaluated for 1 year after the third session, with the primary endpoint being the TLR-free rate at 6 months after VAIVT.
Results: At the third procedure, 24 patients were treated with DCB (DCB group), whereas 26 were treated with SB (SB group). The TLR-free rates at 6 months and 1-year were significantly higher in the DCB group than in the SB group (79.2% vs 26.9%, p < .001; and 41.7% vs 7.7%, p = .005). In the DCB group, a significant correlation was observed between the TLR duration from VAIVT with DCB and the prerestenosis duration before DCB treatment.
Conclusions: Among patients with repeated short-term restenosis after VAIVT, DCB use significantly improved short-term patency compared with that after SB use. DCB may help extend the period between sessions, which are repeated in the short term, to an acceptable length.
背景:药物包被气球(DCB)用于血管通路介入治疗(VAIVT)。然而,很少有研究报道使用标准球囊(SB)对VAIVT后反复出现短期再狭窄的患者,并且DCB对这些患者通畅的影响尚不清楚。目的:本研究旨在评价DCB对sbs VAIVT术后反复短期再狭窄患者的疗效。材料和方法:单中心回顾性研究。我们招募了50名连续患者,他们在VAIVT合并SB后6个月内连续发生两次再狭窄。在第三期,患者接受DCB或SB治疗。在第三期后的1年内评估靶病变血运重建(TLR),主要终点是VAIVT后6个月TLR的无害率。结果:第三道手术中,DCB组24例,SB组26例。DCB组6个月和1年tlr无自由基率显著高于SB组(79.2% vs 26.9%, p < 0.001;41.7% vs 7.7%, p = 0.005)。在DCB组中,从VAIVT到DCB的TLR持续时间与DCB治疗前的预狭窄持续时间之间存在显著相关性。结论:在VAIVT后反复出现短期再狭窄的患者中,与使用SB相比,使用DCB可显著改善短期通畅。DCB可以帮助延长会议之间的时间,这些会议在短期内重复,到一个可接受的长度。